Scholar Rock Presents Data for SRK-015 at the SMA Europe 2nd International Scientific Congress
06 févr. 2020 07h53 HE
|
Scholar Rock
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
09 janv. 2020 07h30 HE
|
Scholar Rock
Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...
Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
19 nov. 2019 07h30 HE
|
Scholar Rock
Biomarker results confirm presence of latent myostatin in patients with SMA, further supporting relevance of drug target in diseaseSRK-015 demonstrated robust and dose-dependent target engagementData...
Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
02 oct. 2019 07h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth...
Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
05 sept. 2019 07h30 HE
|
Scholar Rock
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 16h01 HE
|
Scholar Rock
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
19 juin 2019 07h30 HE
|
Scholar Rock
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
03 juin 2019 16h05 HE
|
Scholar Rock
- SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) - Pharmacodynamic results...
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
28 mai 2019 16h05 HE
|
Scholar Rock
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
08 mai 2019 16h05 HE
|
Scholar Rock
Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Preliminary PK/PD data from a subset of patients are anticipated by...